Alturas Minerals Corp.

0.01

Canada & Ontario Toronto

1 Toronto Street, Suite 201

+1 416 363-4900

www.alturasminerals.com

Looking to explore investment opportunities with ALT?

Contact ALT >

Looking to explore investment opportunities with ALT?

Contact ALT >

Is this your business?
Customize your listing.

CLAIM THIS LISTING

Is this your business?
Customize your listing.

Company Press Releases

Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection

NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprotection HepTcell vaccine was well tolerated but T-cell immunogenicity results were inconclusive GAITHERSBURG, Md., March 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced positive data from its Phase 2a study of NasoVAX intranasal influenza vaccine and provided an update on its Phase 1b study of HepTcell targeted immunotherapy in chronic hepatitis B infection. Results from the Phase 2a study of NasoVAX™ intranasa...

Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference

GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco. Presentation Details - H.C. Wainwright Global Life Sciences ConferenceDate: Tuesday, April 10, 2018Time: 9:25am Eastern Time/3:25pm Central European TimeLocation: LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-MeridionalWebcast:&#...

Altimmune to Announce Year End 2017 Financial Results on March 29

GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29. Conference Call Details   Date:  Thursday, March 29Time:  8:30am Eastern TimeDomestic:  866-548-4713International:  323-794-2093Conference ID:  6280732Webcast:  http://public.viavid.com/index.php?id=128569 ...

See All >

Company News

See All >

NEWSLETTER